/

TLPH

Talphera, Inc.Closed

1.07−0.01 −0.93%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

1.08

Prev close

1.08

Day range

1.061.08

52-week range

0.69001.57

Volume

62.82K0.30×

Mkt cap

55.54M

P/E ttm

—

Fwd P/E

-4.79

EPS ttm

-0.2600

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−31.85%

Price Chart

Yahoo Finance · delayed

TLPHOct 13, 2026O 1.08H 1.08L 1.06C 1.07−0.01 (−0.93%)Vol 62.80K

SMA 501.21
SMA 2001.01

1Y change −8.55% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

TLPH Talphera, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.60%
1 month: −13.71%
3 months: −24.11%
6 months: +25.88%
Year to date: −6.14%
1 year: −8.55%

Valuation & ownership

Market cap: 55.54M
Enterprise value: 44.96M
P/E (ttm): —
Forward P/E: -4.79
PEG ratio: —
Price / book: 3.85
Price / sales (ttm): 55539.20
EV / EBITDA: —
EPS (ttm): -0.2600
EPS (forward): -0.2233
Beta (5y monthly): 0.68
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 51.91M
Float: 25.23M
Short % of float: 1.71%
Short ratio (days): 6.57
Held by insiders: 21.41%
Held by institutions: 46.03%
Avg volume (3m): 211.33K
50-day average: 1.21
200-day average: 1.01
52-week change: −8.55%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 35.1
vs 50-day SMA: −11.48%
vs 200-day SMA: +5.48%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.03%
Realised vol (20d, ann.): 33.4%
From 52-week high: −31.85%
From 52-week low: +55.07%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

3.13

+192.06% implied

Low 3.00Median 3.00High 3.50

Recommendation trend

Now4 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →

DES

About Talphera, Inc.

Yahoo Finance profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 12
Headquarters: San Mateo, CA, United States
Website: talphera.com
Officers: Mr. Vincent J. Angotti CEO & Director
Mr. Raffi Mark Asadorian Chief Financial Officer
Dr. Shakil Aslam M.D. Chief Medical Officer
Mr. Anil N. Dasu Chief Engineering Officer

SEAS

Seasonality · TLPH

2011–2026 · monthly returns

Strongest month Jan +13.58%Weakest month Dec −11.34%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-15.8	-5.2	-17.6	21.3	-9.9	25.6	24.3	-7.0	-2.5	-7.8			−6.1%
2025	23.1	-12.5	-10.7	-2.0	0.0	-6.1	-8.7	28.6	64.8	50.6	-0.7	-14.3	+119.2%
2024	40.5	30.8	-24.3	0.0	0.0	-13.6	11.2	5.1	-17.3	9.3	-24.5	-26.8	−29.7%
2023	-11.5	-29.0	-53.5	1.5	49.3	11.0	-7.2	0.0	-43.7	-10.3	42.3	0.0	−67.3%
2022	-14.3	-6.3	-35.6	-13.8	-8.0	4.3	-12.5	42.9	-30.0	-37.1	-9.5	-5.4	−79.8%
2021	77.4	-14.5	-9.6	-23.5	6.9	-0.7	-14.5	-5.1	-8.9	-13.7	-26.1	-13.8	−54.8%
2020	-19.4	-22.4	-10.6	36.4	-13.7	-12.9	-9.9	14.7	13.6	20.4	-12.3	-17.3	−41.2%
2019	6.5	36.6	3.6	11.2	-33.1	-2.3	3.2	-10.7	-5.6	-9.1	-7.0	13.4	−8.7%
2018	-6.4	-5.3	16.7	14.3	41.7	-0.6	-17.2	10.7	24.2	7.5	-18.6	-31.5	+13.8%
2017	1.9	15.1	3.3	-17.5	-3.8	-14.0	81.4	-15.4	39.4	-58.7	14.2	-6.5	−21.9%
2016	-6.2	2.8	-17.0	9.7	2.4	-22.3	34.9	-13.2	23.5	-28.0	10.7	-16.1	−32.5%
2015	-0.4	32.2	-56.4	3.4	-12.3	21.1	-2.8	3.9	-28.7	29.2	45.2	-32.7	−42.8%
2014	1.0	0.1	5.1	-9.9	-15.0	11.4	-32.1	2.7	-23.2	20.8	0.5	1.1	−40.5%
2013	26.1	-6.9	3.2	13.6	52.0	4.0	25.7	-14.9	8.8	-37.7	45.5	15.6	+165.5%
2012	71.9	-14.5	23.8	3.2	-18.1	10.2	-10.2	2.7	6.3	-6.0	42.0	0.0	+121.9%
2011			-5.2	-0.3	40.4	-4.4	-10.7	-17.1	-5.6	-7.8	1.0	-35.8	−47.0%

INSD

Insider Activity · TLPH

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 21, 2026	Wan Mark AllenDirector	Stock Award(Grant) at price 0.00 per share.	5.1K	—
Jun 21, 2026	Hoffman Stephen J. M.D., Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	5.1K	—
Jun 21, 2026	Adams AdrianDirector	Stock Award(Grant) at price 0.00 per share.	5.1K	—
Jun 21, 2026	Broadfoot Jill MarieDirector	Stock Award(Grant) at price 0.00 per share.	5.1K	—
Jun 21, 2026	Todisco JosephDirector	Stock Award(Grant) at price 0.00 per share.	5.1K	—
Jun 21, 2026	Bozilenko MarinaDirector	Stock Award(Grant) at price 0.00 per share.	5.1K	—
Jun 21, 2026	Jain AbhinavDirector	Stock Award(Grant) at price 0.00 per share.	5.1K	—
Mar 12, 2026	Angotti Vincent JChief Executive Officer	Purchase at price 0.80 per share.	213.3K	$169.97K
Feb 11, 2026	Angotti Vincent JChief Executive Officer	Purchase at price 0.81 per share.	105.4K	$85.59K
Feb 11, 2026	Dasu Badri NOfficer	Purchase at price 0.81 per share.	35K	$28.43K
Feb 11, 2026	Asadorian RaffiChief Financial Officer	Purchase at price 0.81 per share.	45K	$36.55K
Feb 11, 2026	Aslam ShakilOfficer	Purchase at price 0.81 per share.	35K	$28.43K
Oct 22, 2025	Wan Mark AllenDirector	Stock Award(Grant) at price 0.00 per share.	4.3K	—
Oct 22, 2025	Hoffman Stephen J. M.D., Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	4.3K	—
Oct 22, 2025	Adams AdrianDirector	Stock Award(Grant) at price 0.00 per share.	4.3K	—
Oct 22, 2025	Broadfoot Jill MarieDirector	Stock Award(Grant) at price 0.00 per share.	4.3K	—
Oct 22, 2025	Bozilenko MarinaDirector	Stock Award(Grant) at price 0.00 per share.	4.3K	—
Oct 22, 2025	Jain AbhinavDirector	Stock Award(Grant) at price 0.00 per share.	4.3K	—
Oct 14, 2025	Todisco JosephDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Apr 1, 2025	Angotti Vincent JChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	61K	—

13F

Investors Holding TLPH

latest 13F filings of 29 followed managers

Investors holding TLPH
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$116.7K	0.00%	113.30K	−52%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

TLPH

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

TLPH

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Talphera, Inc.

Seasonality · TLPH

Insider Activity · TLPH

Congress Trades · TLPH

Investors Holding TLPH

Investors Holding TLPH

Congress Trades · TLPH

Insider Activity · TLPH

Seasonality · TLPH

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Talphera, Inc.

Earnings & Dividends

News